



Pharma Funded Aseptic Compounding Service.

Introduction to Sciensus.

At Sciensus, we're proud to be a leading healthcare provider. For 30 years, we've worked in partnership with the NHS, private medical providers and pharmaceutical companies to bring patients the life-changing treatment they need, in the comfort and convenience of their own homes.

Today we're a 1,700-strong team, delivering complex clinical care and medication services to over 200,000 diverse patients across the UK and Europe. Together, we're dedicated to helping each and every patient make the most of their medicine, wherever they are.

So, using unparalleled insights, cutting-edge research and intuitive technology, we connect with people powerfully and personally, focusing on their unique needs, empowering them to achieve their goals, and supporting them every step of the way.



About the service.

The Sciensus Pharma Funded Aseptic Compounding Service provides an end-to-end solution for patients to receive medicines which have been aseptically prepared. The service, which utilises the Sciensus Centralised Pharmacy, state of the art compounding unit, nationwide GDP distribution network and university accredited nursing teams provides a solution to maximise medicine use.

The service reduces NHS capacity constraints and ensures patients receive medicines quickly. The service, which is funded by pharmaceutical companies, allows the NHS to only pay for medicines prescribed whilst service fees are paid for by the pharmaceutical company.

The service benefits from the Sciensus GMP Aseptic Compounding Unit, operating under an MHRA MS licence, to prepare and supply patients with aseptic medicines. The Sciensus compounding unit uses gassing isolators and the manufacturing process utilises barcoding, imaging and gravimetrics to provide assurance.

Products are delivered to patients via a Sciensus nurse and, throughout the distribution process, GDP is maintained. Our nursing teams are based across the UK and have completed university accredited courses for the administration of the product to ensure patient safety is maintained at all times.

Key benefits to the NHS:

- Reduces capacity constraints and SACT backlog
- Reduces patients time to first dose
- Low risk of medicine waste
- Favourable purchasing (payment 30 days after administration)
- Improved patient experience due to administration location


To pharmaceutical companies, this service is a wraparound to the provision of their medicines. Medicines are safely supplied by Sciensus specialty pharmacy and quickly, patients can receive medicines by Sciensus nurses. The service also provides assurance of pharmacovigilance throughout.

If you would like to discuss further, please contact
Christopher Appleby, Business Development
Director - Specialist Services

Phone: **07827 831117**

Email: **christopher.appleby@sciensus.com**

[sciensus.com](https://www.sciensus.com)

Sciensus and  logo are registered trademarks.
Sciensus Pharma Services Limited. Registered in England and Wales. Company No: 2759609.
Registered Office: 107 Station Street, Burton on Trent, Staffordshire, DE14 1SZ, UK.



PAR2960822 Implementation Date: 08/08/2022